A new method to personalize treatment for iodine-refractory thyroid cancer
Official title: A Novel Assay to Individualize Resensitization of Iodine-Refractory Thyroid Cancer
Funded at Stanford University · NIH-11075322 · Data updated 2026-11-12
This study is looking for better ways to treat patients with iodine-refractory thyroid cancer by creating tiny models of the cancer to test new treatments that might help the cancer cells absorb radioactive iodine again, which could lead to more personalized and effective care for you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $216,546 |
| NIH project number | 5R61CA278459-03 |
| Project ID | NIH-11075322 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with iodine-refractory thyroid cancer who have limited treatment options.
✕Less likely to help
Patients with early-stage thyroid cancer or those who are not iodine-refractory may not benefit from this research.
What this research studies
This research focuses on improving treatment options for patients with iodine-refractory thyroid cancer, a condition where cancer cells can no longer absorb radioactive iodine, which is crucial for effective treatment. The project aims to develop organoid models of papillary thyroid carcinoma to test and optimize redifferentiation agents that can restore the cancer cells' ability to uptake radioactive iodine. By creating a high-throughput assay, the researchers will be able to analyze thousands of tumor organoid cultures to identify the most effective treatments for individual patients. This personalized approach could lead to better management of the disease and improved outcomes for patients.
Why it matters
Potential benefit: If successful, this research could significantly enhance treatment options and survival rates for patients with iodine-refractory thyroid cancer.
How similar studies have gone: Other research has shown promise in using redifferentiation strategies for similar conditions, indicating potential for success in this novel approach.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Pratx, Guillem — Stanford University
- Study coordinator: Pratx, Guillem
Related research
Other NIH-funded projects on the same topics.
-
WTC Dust and Thyroid Cancer Progression in Human Organoids
This grant tests how World Trade Center dust might influence thyroid cancer progression using human thyroid organoids to model real-life exposure.
-
Integrating molecular signals to guide thyroid cancer care
A doctor-scientist team at Brigham and Women’s Hospital is studying how tumor biology and the immune environment can guide personalized monitoring and treatment for differentiated thyroid cancer.
-
Metabolic Imaging to Track Treatment Response in Aggressive Thyroid Cancer
This grant explores a new way to watch how aggressive thyroid cancers respond to treatment using a special MRI technique that tracks tumor metabolism.
-
Adoptive T-cell Therapy for Anaplastic Thyroid Cancer
A patient-focused program explores using patient immune cells engineered to target and fight anaplastic thyroid cancer, especially for those whose cancer has stopped responding to standard treatments.
-
Overcoming Resistance to BRAF Inhibitors in Aggressive Thyroid Cancers
A patient-focused research effort to find new ways to treat difficult thyroid cancers that no longer respond to current BRAF inhibitors.
-
Improving Treatment of Anaplastic Thyroid Cancer with New Therapies and Early Response Checks
This NIH grant aims to advance treatment for a rare, aggressive thyroid cancer by testing new approaches and measuring how tumors respond early in treatment to tailor care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.